Early access to medicines scheme (EAMS) scientific opinion: pembrolizumab for non-small cell lung cancer

EAMS scientific opinion given to pembrolizumab for metastatic non-small cell lung cancer (NSCLC), including the public assessment report.

This publication was withdrawn on

Withdrawn as this product received a marketing authorisation from the European Commission.



This positive scientific opinion was issued to MSD Ltd for pembrolizumab for the treatment of metastatic non-small cell lung cancer (NSCLC).

The scientific opinion includes:

  • a public assessment report
  • a treatment protocol:
    • for healthcare professionals
    • for patients
    • on the pharmacovigilance system


Information and details regarding patient access

For new patients wishing to access EAMS medicines in England, trusts must submit an application form to to register the patient with NHS England. The form itself can be requested from the same dedicated EAMS email address. Plans are underway to introduce a web based application form as soon as possible. Trusts will be informed when this is available.

For information about access in Northern Ireland, contact Mark Timoney, Chief Pharmaceutical Officer at and Joe Magee, Secondary Care Directorate at

For information about access in Scotland contact the Scottish Government Directorate General Health & Social Care email and elisabeth.campbell@gov.soct.

For information about access in Wales, contact the Welsh Government Department of Health and Social Services by emailing Andrew Evans, Interim Chief Pharmaceutical Officer at and Karen Eveleigh, Head of Pharmacy and Prescribing policy at

Published 15 March 2016
Last updated 23 August 2016 + show all updates
  1. Updating public assessment report.
  2. Updated documents.
  3. Removed "RCC" from first attachment title.
  4. First published.